PROGRAM
Monday, May 17th
14:00
Welcome

Claudia Lanari, IBYME-CONICET, Buenos Aires, Argentina.

 Pfizer Opening Conference:
Chairs: Santiago Bella, Sanatorio Allende y Clínica Universitaria Reina Fabiola, Córdoba, Argentina and José Luis Bocco, CIBICI – CONICET, Córdoba, Argentina
14:15-15:15 Geoffrey Greene, University of Chicago, Chicago, USA.
Advances in ER Targeted Approaches to Breast Cancer Management

 Session 1 – AMGEN: Tumor heterogeneity and breast cancer therapy

Chairs: Isabel Frahm, Sanatorio Mater Dei, Buenos Aires, Argentina and Albana Gattelli, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina, Marina Simian, INS-CONICET, San Martín, Argentina.

15:30-16:00  Mohamed Bentires-Alj, University of Basel, Basel, Switzerland.
Cancer targeted therapy and tumor heterogeneity: Act locally, think globally
16:00-16:30  Jorge Reis Filho, Memorial Sloan Kettering Cancer Center, New York City, USA.
 Triple-negative breast cancer subtyping: why bother?
16:30-16:45  Catalina Lodillinsky, Instituto “Ángel H. Roffo”, Buenos Aires, Argentina.
 Metastasis-suppressor NME1 controls the invasive switch of breast cancer by regulating MT1-MMP surface clearance
16:45-17:00 Discussion

 Session 2: From hormone receptors to the immune system: the evolution of therapeutic targets in breast cancer

Chairs: Caroline Lamb, IBYME-CONICET, Buenos Aires, Argentina; Fernando Petracci, Instituto Alexander Fleming, Buenos Aires, Argentina and Cecilia Jazmín Proietti, IBYME-CONICET, Buenos Aires, Argentina

17:15-17:45 Carol Lange, University of Minnesota, Minneapolis, USA.
Tracking Steroid Receptor-Driven Changes in Breast Cancer Cell Fate
17:45-18:15 Jennifer Richer, University of Colorado, Aurora, USA.
Breast Cancer Hijacks a Trophoblast-Like Program of Immune Suppression
18:15-18:45 Mariana Salatino, IBYME-CONICET, Buenos Aires, Argentina.
Mifepristone primes antitumor immunity in selected luminal  mammary carcinomas opening the door to immune therapies
18:45-19:00 Andrés Marcos Castellaro, CIQUIBIC-UNC, Córdoba, Argentina.
Tumor-Associated Macrophages Induce Endocrine Therapy Resistance in ER+ Breast Cancer Cells
19:00-19:15 Discussion

 

Tuesday, May 18th

10:30 – 13:00      Poster Session 1

Session 3: Cancer stem cells and de-differentiated phenotype

Chairs: Gonzalo Gómez Abuin, Hospital Alemán, Buenos Aires, Argentina; Mauricio Menacho Márquez, IDICER, CCT-CONICET, Rosario, Argentina and Gastón Soria, CIBICI-CONICET, Córdoba, Argentina.

14:00-14:30 Jochen Maurer, University Hospital RWTH, Aachen, Germany.
Cancer stem cells as disease models in research – opportunities and challenges
14:30-15:00 Paolo Ceppi, University of Southern Denmark, Odense, Denmark.
The activity of thymidylate synthase shapes the de-differentiated phenotype of aggressive breast cancers
15:00-15:30 Robert Clarke, University of Manchester, Manchester, UK.
Cytokine regulation of stem cell activity, endocrine resistance and metastasis
15:30-15:45 Martín Emilio García Solá, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina.
An integrative single-cell transcriptomic atlas of the post-natal mouse mammary gland allows discovery of new developmental trajectories in the luminal compartment
15:45-16:00 Discussion

 Session 4: Mouse models for studying breast cancer initiation and progression

Chairs: Maria Marta Facchinetti, INIBIBB-UNS, Bahía Blanca, Argentina and Edith Kordon, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina.

16:15-16:45 D. Joseph Jerry, University of Massachusetts, Amherst, USA.
Consequences of estrogen exposure among strains of mice: a model for gene and environment interactions
16:45-17:15 Fariba Behbod, University of Kansas, Kansas City, USA.
DCIS progression in the MIND model
17:15-17:45 William Muller, Rosalind and Morris Goodman Cancer Center, Montreal, Canada.
Oncogene-mediated signal transduction in transgenic mouse models of human breast cancer
17:45-18:00 Diego Yair Grinman, Yale School of Medicine, New Haven, USA.
PTHrP overexpression in mammary tumors increases tumorigenesis         and causes anorexia
18:00-18:15 Discussion

 Session 5: Genomics Platforms (Spanish)

Chair: Anibal Nuñez de Pierro, Hospital Fernández, Buenos Aires, Argentina. Co-chairs: Gustavo Helguera, IBYME-CONICET, Buenos Aires, Argentina and Ignacio Mc Lean, Hospital Universitario Austral, Pilar, Argentina.

18:30-19:30         Ernesto Korbenfeld, Hospital Británico, Buenos Aires, Argentina
        Fernando Petracci, Instituto Alexander Fleming, Buenos Aires, Argentina

 

Wednesday, May 19th

10:30 – 13:00       Poster Session 2

Session 6: Genetics and Epigenetics of Breast Cancer

Chairs: Martin Abba, UNLP, La Plata, Argentina; Laura Kass, UNL, Santa Fe, Argentina and María Roque Moreno, IHEM-CONICET, Mendoza, Argentina.

14:00-14:30 Adrian Lee, University of Pittsburgh, Pittsburgh, USA.
Genomics of breast cancer progression
14:30-15:00 Sophie Lelievre, Purdue University College of Veterinary Medicine, West Lafayette, USA.
Environmental epigenetics to fight breast cancer risk and development
15:00-15:30 Guenter Vollmer, Technische Universität Dresden, Dresden, Germany.
Polypharmacology of botanical extracts: Is there a link to breast cancer prevention?
15:30-15:45 Santiago Madera, IBYME – CONICET, Buenos Aires, Argentina.
Targeting ErbB-2 nuclear function induces the interferon signalling       pathway in breast cancer
15:45-16:00 Discussion

 Session 7: Understanding the metastatic cascade to learn how to inhibit tumor progression

Chairs: Daniel Alonso, Universidad Nacional de Quilmes, Bernal, Argentina; Enrique Diaz Cantón, CEMIC, Buenos Aires, Argentina and Mario Rossi, Universidad Austral, Pilar, Argentina.

16:15-16:45 Valerie Weaver, University of California, San Francisco, USA.
Tissue force promotes metabolic reprogramming to drive breast tumor aggression and metastasis
16:45-17:15 John Condeelis, Albert Einstein Cancer Center, Bronx, USA.
The mechanism of metastasis during breast cancer progression and how to inhibit it
17:15-17:45 Julio Aguirre Ghiso, Icahn School of Medicine at Mount Sinai, New York City, USA.
The impact of disseminated cancer cell dormancy on the paradigm of metastasis
17:45-18:00   Juan Garona, Universidad Nacional de Quilmes, Bernal, Argentina.
Drug repurposing of hemostatic compound desmopressin (dDAVP) in triple-negative breast cancer (TNBC): Preclinical antitumor activity on 2D/3D cell growth, chemotaxis, tumor progression and metastatic spread.
18:00-18:15 Virginia Judith Wolos, Instituto Ángel H. Roffo, Buenos Aires, Argentina.
Hypoxic microenvironment is associated with acquired resistance to HER2+ breast cancer immunotherapies
18:15-18:45 Discussion

 Session 8: Round Table – Biorepositories and Sample Management (Spanish)

Chair: Eduardo Sandes, Instituto Ángel H. Roffo, Buenos Aires, Argentina. Co-chair: Fabiana Lubieniecki, Hospital Juan P. Garrahan, Buenos Aires, Argentina.

19:00 – 20:30
Andrea Bosaleh , Hospital Juan P. Garrahan, Buenos Aires, Argentina.
Liliana Virginia Siede, UBA-UMSA, Buenos Aires, Argentina.
Alfredo Molinolo, Moores Cancer Center, UCSD, San Diego, USA.
Gonzalo Ardao,  Hospital Central de las Fuerzas Armadas (HCFFAA), Montevideo, Uruguay.
Ana Palmero, Ministerio de Salud de la Nación,  Buenos Aires, Argentina
Thursday, May 20th

10:30 – 13:00       Poster Session 3

Session 9: Estrogen receptors: their involvement in endocrine resistance and dormancy

Chairs: Luisa A. Helguero, Institute of Biomedicine (iBiMED), University of Aveiro, PortugalIsabel Luthy, IBYME-CONICET, Buenos Aires, Argentina

 14:00-14:30 Steffi Oesterreich, University of Pittsburgh, Pittsburgh, USA.
  ER mutations in breast cancer
14:30-15:00 Todd Miller, University of Dartmouth, Lebanon, USA.
Targeting dormancy in ER+ breast cancer
15:00-15:15 Discussion

Session 10: Novel targets in the era of precision medicine

Chairs: Vanesa Gottifredi, Instituto Leloir, Buenos Aires, Argentina; Adrián Nervo, Instituto Alexander Fleming, Buenos Aires, Argentina and Virginia Novaro, IBYME-CONICET, Buenos Aires, Argentina.

15:30-16:00 Violeta Serra, Vall d’Hebron Institut d’Oncologia (VHIO), Barcelona, Spain.
CDKs and PARP inhibition in breast cancer
16:00-16:15 Santiago Bella, Sanatorio Allende y Clínica Universitaria Reina Fabiola, Córdoba, Argentina.
Use of CDK inhibitors in South America
16:15-16:45 Dejan Juric, Massachusetts General Hospital, Boston, USA.
News on PI3K inhibitors in clinical practice
16:45-17:00 Andrés Elia, IBYME-CONICET, Buenos Aires, Argentina.
Antiproliferative effect of mifepristone in breast cancer patients with higher levels of progesterone receptor A than B: results from the MIPRA trial.
17:00-17:15 Fabiana A. Rossi,  IIMT-CONICET-Univ. Austral, Buenos Aires, Argentina.
USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancer
17:15-17:30 Discussion

Session 11: Round Table – Interaction among government, non-government agencies, and industry for funding and promoting breast cancer translational research (Spanish)

Chair: Omar Coso, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina; Co-chairs: Edith Kordon, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina and Marina Simian, INS-CONICET, San Martin, Argentina.

17:45 – 19:00

Judith Nairdof, Facultad de Filosofía y Letras, UBA-CONICET, Buenos Aires, Argentina.

Rosana Felice, GSK, Buenos Aires, Argentina.

Andrea Llera, Instituto Leloir- CONICET, Buenos Aires, Argentina.

Daniel Gómez, Universidad Nacional de Quilmes-CONICET, Bernal, Argentina.

 

Friday, May 21st

10:30 – 13:00       Poster Session 4

Session 12: Local and systemic therapies

Chairs: Elisa Bal de Kier Joffe, Instituto Ángel H. Roffo, Buenos Aires, Argentina; Pablo Mandó, CEMIC, Buenos Aires, Argentina; Roxana Schillaci, IBYME-CONICET, Buenos Aires, Argentina

14:00-14:30 Catherine Park, University of California, San Francisco, USA.
Radiation oncology- Oligometastasis: The impact of local therapy on systemic disease
14:30-14:45 Victoria Costanzo, Instituto A. Fleming, Buenos Aires, Argentina.
Treatment of Her2+ tumors
14:45-15:00 Florencia Perazzo, CEMIC, Buenos Aires, Argentina.
Immunotherapy for triple negative breast cancer
15:00-15:15 Matthew Winder, CRUK Beatson Institute, Glasgow, United Kingdom.
MCL-1 is a clinically targetable vulnerability in breast cancer
15:15-15:30 Discussion

 Session 13: New developments in diagnosis and epidemiology of breast cancer

Chairs: Roberto Meiss, Academia Nacional de Medicina, Buenos Aires, Argentina and Ángela Solano, Facultad de Medicina-UBA, Buenos Aires, Argentina.

15:45-16:15 Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York City, USA.
cfDNA analysis for breast cancer patients: fact checking
16:15-16:45 Osvaldo Podhajcer. Instituto Leloir, Buenos Aires, Argentina.
The Latin American Cancer Research Network: first precision medicine study in human breast cancer in Latin America
16:45-17:15 Stephen N Birrell, The Breast and Endocrine Center, Adelaide, Australia.
Mammographic breast density -the biological and clinical consequences of an opaque breast?
17:15-17:30 Gabriela Pataccini, IBYME-CONICET, Buenos Aires, Argentina.
A breast cancer patient-derived xenograft biobank for precision medicine studies in Argentina.
17:30-17:45 Discussion
 Closing Conference

 Chairs: J. Silvio Gutkind, UCSD, Moores Cancer Center, San Diego, USA and Pablo Mandó, CEMIC, Buenos Aires, Argentina.

18:00-19:00 Charles Perou, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA.
Quantitative Medicine for Breast Cancer Patients
 
19:00-19:15
Closing words

Edith Kordon, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina.